Similar articles for PMID: 9654110

Year	Number of Results
1990	1
1991	1
1992	2
1993	1
1994	5
1995	4
1996	6
1997	6
1998	11
1999	7
2000	10
2001	5
2002	8
2003	7
2004	3
2005	4
2006	4
2007	1
2008	2
2010	2
2012	3
2013	3
2014	2
2015	2
2016	1
2017	1
2018	2
2021	1
2022	1
2024	0

1

Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC. Vigushin DM, et al. Cancer Chemother Pharmacol. 1998;42(2):111-7. doi: 10.1007/s002800050793. Cancer Chemother Pharmacol. 1998. PMID: 9654110 Clinical Trial.

2

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Hudes GR, et al. Clin Cancer Res. 2000 Aug;6(8):3071-80. Clin Cancer Res. 2000. PMID: 10955786 Clinical Trial.

3

Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content.

Chow HH, Salazar D, Hakim IA. Chow HH, et al. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1472-6. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433729

4

Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry.

Poon GK, Vigushin D, Griggs LJ, Rowlands MG, Coombes RC, Jarman M. Poon GK, et al. Drug Metab Dispos. 1996 May;24(5):565-71. Drug Metab Dispos. 1996. PMID: 8723738 Clinical Trial.

5

Human metabolism of the experimental cancer therapeutic agent d-limonene.

Crowell PL, Elson CE, Bailey HH, Elegbede A, Haag JD, Gould MN. Crowell PL, et al. Cancer Chemother Pharmacol. 1994;35(1):31-7. doi: 10.1007/BF00686281. Cancer Chemother Pharmacol. 1994. PMID: 7987974

6

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH. Ripple GH, et al. Clin Cancer Res. 2000 Feb;6(2):390-6. Clin Cancer Res. 2000. PMID: 10690515 Clinical Trial.

7

Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.

Crowell PL, Lin S, Vedejs E, Gould MN. Crowell PL, et al. Cancer Chemother Pharmacol. 1992;31(3):205-12. doi: 10.1007/BF00685549. Cancer Chemother Pharmacol. 1992. PMID: 1464157

8

Phase I clinical trial of perillyl alcohol administered daily.

Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH. Ripple GH, et al. Clin Cancer Res. 1998 May;4(5):1159-64. Clin Cancer Res. 1998. PMID: 9607573 Clinical Trial.

9

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Drengler RL, et al. J Clin Oncol. 1999 Feb;17(2):685-96. doi: 10.1200/JCO.1999.17.2.685. J Clin Oncol. 1999. PMID: 10080615 Clinical Trial.

10

R-Limonene metabolism in humans and metabolite kinetics after oral administration.

Schmidt L, Göen T. Schmidt L, et al. Arch Toxicol. 2017 Mar;91(3):1175-1185. doi: 10.1007/s00204-016-1751-6. Epub 2016 Jun 21. Arch Toxicol. 2017. PMID: 27325307

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year